Helen Tayton-Martin
2018
Compensation breakdown
| Non-Equity Incentive Plan | $146,331 |
|---|---|
| Option Awards | $730,791 |
| Salary | $382,566 |
| Other | $20,619 |
| Total | $1,280,308 |
Tayton-Martin received $730.8K in option awards, accounting for 57% of the total pay in 2018.
Tayton-Martin also received $146.3K in non-equity incentive plan, $382.6K in salary and $20.6K in other compensation.
Rankings
In 2018, Helen Tayton-Martin's compensation ranked 7,964th out of 14,244 executives tracked by ExecPay. In other words, Tayton-Martin earned more than 44.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,964 out of 14,244 | 44th |
Division Manufacturing | 3,129 out of 5,765 | 46th |
Major group Chemicals And Allied Products | 1,169 out of 2,128 | 45th |
Industry group Drugs | 981 out of 1,817 | 46th |
Industry Biological Products, Except Diagnostic Substances | 187 out of 339 | 45th |
Pay ratio
| Helen Tayton-Martin's Pay | $1,280,308 |
|---|---|
| Median Employee's Pay | $137,800 |
| Pay Ratio | 9to 1 |
In 2018, the annual total compensation of Helen Tayton-Martin was $1,280,308.
The annual total compensation of the median employee at Adaptimmune Therapeutics was $137,800.
The ratio of Helen Tayton-Martin's pay to the pay of median employee was therefore 9 to one.
Tayton-Martin's colleagues
We found four more compensation records of executives who worked with Helen Tayton-Martin at Adaptimmune Therapeutics in 2018.